







C Delles et al.: Aggressive LDL-cholesterol lowering in secondary prevention protocols is associated with improved endothelial function

Supplementary table 1. Lipid targets in secondary prevention

| | | | Total Cholesterol | | LDL Cholesterol | |
|---|------------------|-------------------|-------------------|---------|-----------------|---------|
| | | | minimum | optimum | minimum | optimum |
|  | JBS | 2000 ¹ | <5.0 | - | <3.0 | - |
|  | AHA/ACC | 2001 ² | - | - | <2.6 | - |
|  | Joint Task Force | 2003 ³ | <4.5 | - | <2.5 | - |
|  | JBS | 2005 ⁴ | <5.0 | <4.0 | <3.0 | <2.0 |
|  | AHA/ACC | 2006 ⁵ | - | - | <2.6 | <1.8 |
|  | Joint Task Force | 2007 ⁶ | <4.5 | <4.0 | <2.5 | <2.0 |

References:

1. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. *BMJ*. 2000; 320:705-708.
2. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation*. 2001; 104:1577-1579.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*. 2003; 24:1601-1610.
4. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. *Heart*. 2005; 91 Suppl 5:v1-v52.
5. AHA; ACC; National Heart, Lung, and Blood Institute, Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol*. 2006; 47:2130-2139.
6. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts), Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL; Other experts who contributed to parts of the guidelines; Walma E, Fitzgerald T, Cooney MT, Dudina A; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellems I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Hellems I, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoğlu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. *Eur Heart J* 2007;28:2375-2414.


Supplementary table 2. Clinical characteristics of patients used for comparison of endothelial function between 2003 and 2007

| | 2003 n=36 | 2007 n=36 | <i>P</i> -value |
|--------------------------------------|---------------|--------------|-----------------|
| Age (years) | 62 ± 8 | 63 ± 9 | 0.005 |
| Male/female | 24 / 12 (67%) | 28 / 8 (78%) | 0.430 |
| Body mass index (kg/m ²) | 28.4 ± 4.6 | 30.0 ± 4.7 | 0.302 |
| Systolic blood pressure (mmHg) | 137 ± 13 | 142 ± 29 | 0.413 |
| Diastolic blood pressure (mmHg) | 81 ± 11 | 80 ± 12 | 0.661 |
| Statin dose (mg/d) | 25±8 | 38±16 | 0.007 |

Supplementary table 3. Clinical characteristics of patients used for comparison of vascular superoxide production between 2003 and 2007

| | 2003 n=33 | 2007 n=33 | <i>P</i> -value |
|--------------------------------------|---------------|--------------|-----------------|
| Age (years) | 61 ± 9 | 61 ± 9 | 0.943 |
| Male/female | 19 / 14 (58%) | 24 / 9 (73%) | 0.301 |
| Body mass index (kg/m ²) | 29.5 ± 6.2 | 29.4 ± 4.8 | 0.931 |
| Systolic blood pressure (mmHg) | 136 ± 8 | 133 ± 11 | 0.781 |
| Diastolic blood pressure (mmHg) | 81 ± 10 | 81 ± 10 | 0.952 |
| Statin dose (mg/d) | 32±16 | 36±13 | 0.185 |

Supplementary figure 1.



Correlation between endothelium dependent vasodilation and LDL-cholesterol levels in male patients with CAD in the 2003 and 2007 groups. The correlation ($r=-0.527$) is significant at $P<0.001$.